0001798749false00017987492024-10-112024-10-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2024

AEROVATE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

    

001-40544

    

83-1377888

(State or other jurisdiction

(Commission

(I.R.S. Employer

of incorporation)

File Number)

Identification No.)

Aerovate Therapeutics, Inc.

930 Winter Street, Suite M-500, Waltham, Massachusetts 02451

(Address of principal executive offices, including zip code)

(617) 443-2400

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trade Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

AVTE

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 11, 2024, Aerovate Therapeutics, Inc. (the “Company”) notified the Nasdaq Global Market (“Nasdaq”) that the Company was not currently in compliance with the audit committee composition requirement of Nasdaq Listing Rule 5605(c)(2), due to the Company only having two current members on its audit committee of its board of directors (the “Board”) as a result of the resignation of Maha Katabi, Ph.D. on October 6, 2024, which resignation was previously reported. To resolve this noncompliance, on October 17, 2024, the Board approved the appointment of director Habib J. Dable as a member of the Board’s audit committee, effective as of October 17, 2024. As a result of this appointment, the Company regained compliance with Nasdaq Listing Rule 5605(c)(2).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

104

Cover Page Interactive Data File

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Aerovate Therapeutics, Inc.

Date: October 17, 2024

 

By:

 

 

/s/ George A. Eldridge

 

 

George A. Eldridge

 

 

Chief Financial Officer

v3.24.3
Document and Entity Information
Oct. 11, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 11, 2024
Entity File Number 001-40544
Entity Registrant Name AEROVATE THERAPEUTICS, INC.
Entity Central Index Key 0001798749
Entity Tax Identification Number 83-1377888
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 930 Winter Street
Entity Address, Adress Line Two Suite M-500
Entity Address, City or Town Waltham
Entity Address State Or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 617
Local Phone Number 443-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AVTE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true

Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Aerovate Therapeutics Charts.
Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Aerovate Therapeutics Charts.